Betterlife Pharma Inc. (TSE:BETR) has released an update.
BetterLife Pharma Inc. reports successful results from their GLP animal safety study for BETR-001, a non-hallucinogenic LSD derivative, showing no significant cardiopulmonary safety issues at 100-fold the projected human trial dose. The company highlights BETR-001’s clean safety profile, differentiating it from other serotonergic psychedelics due to its lack of agonism at the 5-HT2B receptor, a common cause of cardiac toxicity. With these promising results, BetterLife is advancing towards completing the remaining studies needed to file an Investigational New Drug application by the end of 2024.
For further insights into TSE:BETR stock, check out TipRanks’ Stock Analysis page.
